Global Recombinant Hormone Market Growth 2025-2031

Publication ID:

LPI04255763

Publication Date:

April 24, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Recombinant Hormone market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Recombinant hormones are hormones that are manufactured in a laboratory using recombinant technology for therapeutic purposes. The endocrine system in the human body consists of glands (pituitary, thyroid, parathyroid, adrenal, pancreas, etc.) that produce hormones that regulate metabolism, growth and development, reproduction, sexual function, tissue function and other functions. If hormone levels are too high or too low, there is a problem with the endocrine system.
United States market for Recombinant Hormone is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Recombinant Hormone is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Recombinant Hormone is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Recombinant Hormone players cover Eli Lilly and Company, Ferring Pharmaceuticals, Merck, Pfizer, Novo Nordisk, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淩ecombinant Hormone Industry Forecast鈥� looks at past sales and reviews total world Recombinant Hormone sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Hormone sales for 2025 through 2031. With Recombinant Hormone sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Hormone industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Hormone landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Hormone portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Recombinant Hormone market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Hormone and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Hormone.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Hormone market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Growth Hormone
Insulin
Follicle-stimulating Hormone
Others
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Eli Lilly and Company
Ferring Pharmaceuticals
Merck
Pfizer
Novo Nordisk
Novartis AG
Ipsen
LG Chem
Teva Pharmaceutical
Scripps Laboratories
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Hormone market?
What factors are driving Recombinant Hormone market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Hormone market opportunities vary by end market size?
How does Recombinant Hormone break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Recombinant Hormone Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Recombinant Hormone by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Recombinant Hormone by Country/Region, 2020, 2024 & 2031
2.2 Recombinant Hormone Segment by Type
2.2.1 Growth Hormone
2.2.2 Insulin
2.2.3 Follicle-stimulating Hormone
2.2.4 Others
2.3 Recombinant Hormone Sales by Type
2.3.1 Global Recombinant Hormone Sales Market Share by Type (2020-2025)
2.3.2 Global Recombinant Hormone Revenue and Market Share by Type (2020-2025)
2.3.3 Global Recombinant Hormone Sale Price by Type (2020-2025)
2.4 Recombinant Hormone Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Recombinant Hormone Sales by Application
2.5.1 Global Recombinant Hormone Sale Market Share by Application (2020-2025)
2.5.2 Global Recombinant Hormone Revenue and Market Share by Application (2020-2025)
2.5.3 Global Recombinant Hormone Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Recombinant Hormone Breakdown Data by Company
3.1.1 Global Recombinant Hormone Annual Sales by Company (2020-2025)
3.1.2 Global Recombinant Hormone Sales Market Share by Company (2020-2025)
3.2 Global Recombinant Hormone Annual Revenue by Company (2020-2025)
3.2.1 Global Recombinant Hormone Revenue by Company (2020-2025)
3.2.2 Global Recombinant Hormone Revenue Market Share by Company (2020-2025)
3.3 Global Recombinant Hormone Sale Price by Company
3.4 Key Manufacturers Recombinant Hormone Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Hormone Product Location Distribution
3.4.2 Players Recombinant Hormone Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Recombinant Hormone by Geographic Region
4.1 World Historic Recombinant Hormone Market Size by Geographic Region (2020-2025)
4.1.1 Global Recombinant Hormone Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Recombinant Hormone Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Recombinant Hormone Market Size by Country/Region (2020-2025)
4.2.1 Global Recombinant Hormone Annual Sales by Country/Region (2020-2025)
4.2.2 Global Recombinant Hormone Annual Revenue by Country/Region (2020-2025)
4.3 Americas Recombinant Hormone Sales Growth
4.4 APAC Recombinant Hormone Sales Growth
4.5 Europe Recombinant Hormone Sales Growth
4.6 Middle East & Africa Recombinant Hormone Sales Growth
5 Americas
5.1 Americas Recombinant Hormone Sales by Country
5.1.1 Americas Recombinant Hormone Sales by Country (2020-2025)
5.1.2 Americas Recombinant Hormone Revenue by Country (2020-2025)
5.2 Americas Recombinant Hormone Sales by Type (2020-2025)
5.3 Americas Recombinant Hormone Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Hormone Sales by Region
6.1.1 APAC Recombinant Hormone Sales by Region (2020-2025)
6.1.2 APAC Recombinant Hormone Revenue by Region (2020-2025)
6.2 APAC Recombinant Hormone Sales by Type (2020-2025)
6.3 APAC Recombinant Hormone Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Recombinant Hormone by Country
7.1.1 Europe Recombinant Hormone Sales by Country (2020-2025)
7.1.2 Europe Recombinant Hormone Revenue by Country (2020-2025)
7.2 Europe Recombinant Hormone Sales by Type (2020-2025)
7.3 Europe Recombinant Hormone Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant Hormone by Country
8.1.1 Middle East & Africa Recombinant Hormone Sales by Country (2020-2025)
8.1.2 Middle East & Africa Recombinant Hormone Revenue by Country (2020-2025)
8.2 Middle East & Africa Recombinant Hormone Sales by Type (2020-2025)
8.3 Middle East & Africa Recombinant Hormone Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Hormone
10.3 Manufacturing Process Analysis of Recombinant Hormone
10.4 Industry Chain Structure of Recombinant Hormone
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Hormone Distributors
11.3 Recombinant Hormone Customer
12 World Forecast Review for Recombinant Hormone by Geographic Region
12.1 Global Recombinant Hormone Market Size Forecast by Region
12.1.1 Global Recombinant Hormone Forecast by Region (2026-2031)
12.1.2 Global Recombinant Hormone Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Recombinant Hormone Forecast by Type (2026-2031)
12.7 Global Recombinant Hormone Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Eli Lilly and Company
13.1.1 Eli Lilly and Company Company Information
13.1.2 Eli Lilly and Company Recombinant Hormone Product Portfolios and Specifications
13.1.3 Eli Lilly and Company Recombinant Hormone Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Eli Lilly and Company Main Business Overview
13.1.5 Eli Lilly and Company Latest Developments
13.2 Ferring Pharmaceuticals
13.2.1 Ferring Pharmaceuticals Company Information
13.2.2 Ferring Pharmaceuticals Recombinant Hormone Product Portfolios and Specifications
13.2.3 Ferring Pharmaceuticals Recombinant Hormone Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Ferring Pharmaceuticals Main Business Overview
13.2.5 Ferring Pharmaceuticals Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Recombinant Hormone Product Portfolios and Specifications
13.3.3 Merck Recombinant Hormone Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Recombinant Hormone Product Portfolios and Specifications
13.4.3 Pfizer Recombinant Hormone Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Novo Nordisk
13.5.1 Novo Nordisk Company Information
13.5.2 Novo Nordisk Recombinant Hormone Product Portfolios and Specifications
13.5.3 Novo Nordisk Recombinant Hormone Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Novo Nordisk Main Business Overview
13.5.5 Novo Nordisk Latest Developments
13.6 Novartis AG
13.6.1 Novartis AG Company Information
13.6.2 Novartis AG Recombinant Hormone Product Portfolios and Specifications
13.6.3 Novartis AG Recombinant Hormone Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Novartis AG Main Business Overview
13.6.5 Novartis AG Latest Developments
13.7 Ipsen
13.7.1 Ipsen Company Information
13.7.2 Ipsen Recombinant Hormone Product Portfolios and Specifications
13.7.3 Ipsen Recombinant Hormone Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Ipsen Main Business Overview
13.7.5 Ipsen Latest Developments
13.8 LG Chem
13.8.1 LG Chem Company Information
13.8.2 LG Chem Recombinant Hormone Product Portfolios and Specifications
13.8.3 LG Chem Recombinant Hormone Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 LG Chem Main Business Overview
13.8.5 LG Chem Latest Developments
13.9 Teva Pharmaceutical
13.9.1 Teva Pharmaceutical Company Information
13.9.2 Teva Pharmaceutical Recombinant Hormone Product Portfolios and Specifications
13.9.3 Teva Pharmaceutical Recombinant Hormone Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Teva Pharmaceutical Main Business Overview
13.9.5 Teva Pharmaceutical Latest Developments
13.10 Scripps Laboratories
13.10.1 Scripps Laboratories Company Information
13.10.2 Scripps Laboratories Recombinant Hormone Product Portfolios and Specifications
13.10.3 Scripps Laboratories Recombinant Hormone Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Scripps Laboratories Main Business Overview
13.10.5 Scripps Laboratories Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂